Browse Studies — Arctuva

Phase 3

Evaluating Novel Therapies and ctDNA as a Marker in Curatively-Treated Gastrointestinal Cancers With Microscopic Residual Disease

This study is a non-randomized, open-label, multi-cohort, multi-site, pilot feasibility therapeutic trial. The study will enroll 20 patients across 4 cohorts (…

Colon AdenocarcinomaRectal AdenocarcinomaGastric Adenocarcinoma+4 more

Estimated

~$10 – $6,250

Georgetown UniversityNCT05482516

Phase 2

Phase II Prospective, Open Label Randomized Controlled Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy …

Foregut AdenocarcinomaEsophageal AdenocarcinomaGastroesophageal Adenocarcinoma+6 more

Estimated

~$10 – $6,250

Yale UniversityNCT07282912

Phase 1

Safety and Feasibility of Prophylactic Heated Intra-peritoneal Chemotherapy (HIPEC) for High-Risk Gallbladder Adenocarcinoma

Gallbladder adenocarcinoma is a devastating disease associated with a poor prognosis. Gallbladder and other biliary cancers will be responsible for an estimate…

Gallbladder Adenocarcinoma

Estimated

~$10 – $6,250

West Virginia UniversityNCT05430035